This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Dabigatran
- DrugBank Accession Number
- DB14726
- Background
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Dabigatran (DB14726)
- Weight
- Average: 471.521
Monoisotopic: 471.201887693 - Chemical Formula
- C25H25N7O3
- Synonyms
- Dabigatran
- External IDs
- BIBR 953 ZW
- BIBR-953
- BIBR-953-ZW
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding can be increased when Abciximab is combined with Dabigatran. Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Dabigatran. Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dabigatran. Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Dabigatran. Albutrepenonacog alfa The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dabigatran. Alclofenac The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Dabigatran. Aldesleukin The risk or severity of bleeding can be increased when Dabigatran is combined with Aldesleukin. Alemtuzumab The risk or severity of bleeding can be increased when Dabigatran is combined with Alemtuzumab. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Dabigatran. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Pradaxa
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- I0VM4M70GC
- CAS number
- 211914-51-1
- InChI Key
- YBSJFWOBGCMAKL-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
- IUPAC Name
- 3-[1-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido]propanoic acid
- SMILES
- CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(=C2)C(=O)N(CCC(O)=O)C1=NC=CC=C1
References
- General References
- Not Available
- External Links
- KEGG Drug
- D09707
- ChemSpider
- 187412
- BindingDB
- 50112086
- 1546356
- ChEBI
- 70752
- ChEMBL
- CHEMBL48361
- ZINC
- ZINC000001910616
- PDBe Ligand
- 4CC
- Wikipedia
- Dabigatran
- PDB Entries
- 4jn2 / 4yhi / 4yhk / 4yhm / 4yho
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Atrial Fibrillation / Device Related Thrombus / Left Atrial Appendage Thrombosis / Watchman LAA Closure Device 1 4 Completed Basic Science Acute Coronary Syndrome (ACS) / Atrial Fibrillation 1 4 Completed Basic Science Venous Thromboembolism 1 4 Completed Other Cerebral Ischemic Events / Cognitive Dysfunctions / Dementia 1 4 Completed Other Post-operative Atrial Fibrillation (POAF) 1 4 Completed Prevention Atrial Fibrillation 3 4 Completed Prevention Premature Ventricular Contraction (PVC) / Stroke / Ventricular Tachycardia (VT) 1 4 Completed Treatment Atrial Fibrillation 3 4 Completed Treatment Atrial Fibrillation / Atrial Flutter 1 4 Completed Treatment Atrial Fibrillation / Cardioembolic Events / Oral Anticoagulation 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0975 mg/mL ALOGPS logP 2.37 ALOGPS logP 0.077 Chemaxon logS -3.7 ALOGPS pKa (Strongest Acidic) 3.18 Chemaxon pKa (Strongest Basic) 12.52 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 150.22 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 143.26 m3·mol-1 Chemaxon Polarizability 50.96 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 14, 2018 17:30 / Updated at June 26, 2021 13:10